A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors.

Gun Min Kim, Tony Reid, Sang Joon Shin, Sun Young Rha, Joong Bae Ahn, Sung Sil Lee, Hyun Cheol Chung

Abstract readClinical Trial, Phase IMulticenter Study

In one paragraph

Article in Investigational new drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gun Min KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.

Tony ReidClinical Medicine/Hematology and Oncology, University of California, San Diego, Moores UCSD Cancer Center, California, USA.

Sang Joon ShinDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.

Sun Young RhaDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.

Joong Bae AhnDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.

Sung Sil LeeMedical Division, Green Cross Corporation, Yongin, South Korea.

Hyun Cheol ChungDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. unchung8@yuhs.ac.

Funding

Korea Health Industry Development Institute HI05C0178

6 · The paper itself

Abstract

Purpose MG1102 is a potent inhibitor of angiogenesis in both in vitro and in vivo models. The purpose of the study was to investigate the safety and tolerability, pharmacokinetic (PK) profile, and preliminary antitumor efficacy of MG1102. Methods Patients with refractory solid tumors were eligible. Each patient received 1 dose of MG1102 followed by a 6-day rest period, during which they underwent PK assessments and safety monitoring. If the initial dose was tolerated, the patient continued with the 21-day treatment of MG1102 (5 days on, 2 days off for 3 weeks). Dose escalation was planned in 6 cohorts (6, 12, 24, 48, 96, and 192 mg/m

Indexed as

AgedAged, 80 and overApolipoproteins ACohort StudiesDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansMaleMaximum Tolerated DoseMiddle AgedNeoplasmsPeptide FragmentsPrognosisSafetyApolipoproteins ALK8 peptidePeptide FragmentsAngiogenesis inhibitorMG1102Phase ISolid tumor

Identifiers

PMID28353123

DOI10.1007/s10637-017-0460-1

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.